Previous 10 | Next 10 |
Kala Pharmaceuticals (NASDAQ:KALA) said that UnitedHealthcare (NYSE:UNH) added dry eye disease therapy Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022, expanding commercial coverage to 118M people. In ...
-- Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives -- ARLINGTON, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and ...
Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...
Short squeeze stocks are becoming a mainstay in the arsenal of trends to follow this year. Thanks to extensive breakouts from the likes of AMC Entertainment ( NYSE: AMC ), GameStop ( NYSE: GME ), and countless others, retail traders, in particular, are on the hunt for the next r...
WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with Nasdaq Listing ...
The following slide deck was published by Kala Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Kala Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation
Kala Pharmaceuticals, Inc. (KALA) Q3 2021 Earnings Conference Call November 15, 2021 08:30 AM ET Company Participants Jill Steier – Executive Director, Investor Relations and Corporate Communications Mark Iwicki – Chairman, President and Chief Executive Officer Kim Brazzell ...
Kala Pharmaceuticals (KALA +3.4%) has acquired privately held Combangio gaining access to a candidate for persistent corneal epithelial defect ("PCED"). Terms call Combangio equityholders to receive $5M upfront, and an aggregate of 7,788,667 shares of Kala common stock with an aggregate value...
If you’re looking for the best penny stocks to buy now, you might be looking at different trends. Whether they be industry trends or something more thematic, there’s no shortage of attention-grabbing catalysts. In the stock market today, everything from electric vehicles to en...
Kala Pharmaceuticals (NASDAQ:KALA): Q3 GAAP EPS of -$0.43 in-line. Revenue of $3.1M (+39.6% Y/Y) misses by $2.06M. Press Release As of September 30, 2021, Kala had cash and cash equivalents of $124.5M, compared to $149.6M of cash, cash equivalents and short-term investments as of June 30, 202...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...